Physician profile
Joya Paul
NPI 1770730095
$953.94
in general payments reported to CMS, 2019-2025
16 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.78 · 2022: $427 · 2023: $129 · 2024: $31.80 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $239.21 | 2022-2025 | Inspire |
| Lilly USA, LLC | $171.79 | 2022-2025 | Zepbound |
| Banner Life Sciences, LLC | $125.67 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $70.81 | 2022-2023 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $62.76 | 2021-2023 | Ultomiris |
| Jazz Pharmaceuticals INC. | $60.23 | 2025 | |
| Insulet Corporation | $37.06 | 2022 | |
| Impel Pharmaceuticals INC. | $27.28 | 2023 | Trudhesa |
| Biogen, INC. | $24.16 | 2022 | |
| Ucb, INC. | $23.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.24 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.02 | 2023 | Onpattro |
| Teva Pharmaceuticals USA, INC. | $20.53 | 2023 | Austedo |
| Genentech USA, INC. | $19.61 | 2021 | |
| Abbvie INC. | $17.43 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joya Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.